Cancer Control (Aug 2022)

An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership

  • Charlotte Lynch BSc, MSc,
  • Samantha Harrison BSc, MSc,
  • John Butler MRCOG, MBBS, BSc,
  • David R. Baldwin MA, DM, FRCPsych, FRSA, FHEA,
  • Paul Dawkins MB ChB, MRCP, CCT Resp Med and Gen (Int) Med, FRCP 2012, FRACP,
  • Joris van der Horst MD, FRCP,
  • Erik Jakobsen MD, MPM,
  • Jonathan McAleese MD,
  • Annette McWilliams MBBS,
  • Karen Redmond MB BCh NUI,
  • Anand Swaminath MD, MSc, FRCPC,
  • Christian J. Finley MD, MPH

Journal volume & issue
Vol. 29


Read online

Background Research from the International Cancer Benchmarking Partnership (ICBP) demonstrates that international variation in lung cancer survival persists, particularly within early stage disease. There is a lack of international consensus on the critical contributing components to variation in lung cancer outcomes and the steps needed to optimise lung cancer services. These are needed to improve the quality of options for and equitable access to treatment, and ultimately improve survival. Methods Semi-structured interviews were conducted with 9 key informants from ICBP countries. An international clinical network representing 6 ICBP countries (Australia, Canada, Denmark, England, Ireland, New Zealand, Northern Ireland, Scotland & Wales) was established to share local clinical insights and examples of best practice. Using a modified Delphi consensus model, network members suggested and rated recommendations to optimise the management of lung cancer. Calls to Action were developed via Delphi voting as the most crucial recommendations, with Good Practice Points included to support their implementation. Results Five Calls to Action and thirteen Good Practice Points applicable to high income, comparable countries were developed and achieved 100% consensus. Calls to Action include (1) Implement cost-effective, clinically efficacious, and equitable lung cancer screening initiatives; (2) Ensure diagnosis of lung cancer within 30 days of referral; (3) Develop Thoracic Centres of Excellence; (4) Undertake an international audit of lung cancer care; and (5) Recognise improvements in lung cancer care and outcomes as a priority in cancer policy. Conclusion The recommendations presented are the voice of an expert international lung cancer clinical network, and signpost key considerations for policymakers in countries within the ICBP but also in other comparable high-income countries. These define a roadmap to help align and focus efforts in improving outcomes and management of lung cancer patients globally.